Tripos Announces Partnerships with Pharmaceutical and Life Science Companies
News Jan 27, 2006
Tripos, Inc. has announced collaborations with several prominent pharmaceutical and life science organizations across Europe and North America to provide knowledge-driven customized chemistry services.
These agreements encompass a combination of partnerships and extensions with CeNeS Ltd., Gemin X Biotechnologies Inc., Genzyme Corp., GlaxoSmithKline Research and Development Ltd., and Schering-Plough Research Institute.
Drawing upon Tripos' proprietary knowledge-driven chemistry process, the partnerships encompass a range of research activities including medicinal chemistry programs, the development of LeadQuest® compounds, follow-up libraries based on hits from LeadQuest, provision of synthetic protocols, fragment-based screening and LeadHopping® projects.
"Tripos is delighted to be working with these pioneering pharmaceutical and life science companies," said Dr. John P. McAlister, president and CEO of Tripos.
"Their decision to select Tripos Discovery Research as their drug discovery partner underscores the quality of our work, the innovation we bring to our partners and our solid reputation for success in this field."
"As we enter 2006, we are committed to expanding our service and client base to provide more integrated drug discovery services."
"We are now engaged in more discovery research programs than ever before, and we look forward to generating value on behalf of our clients."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE